Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT06690281
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
- Conditions
- Locally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Pancreatic Ductal AdenocarcinomaLocally Advanced Renal Cell CarcinomaMetastatic Cervical CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Melanoma
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT06626256
- Locations
- πΊπΈ
City of Hope Medical Center, Duarte, California, United States
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT06427694
- Locations
- π¬π§
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 210
- Registration Number
- NCT06253520
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 15
- Registration Number
- NCT06236425
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 10
- Registration Number
- NCT06204991
Low Dose IL2 Immunotherapy in AD
- Conditions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 8
- Registration Number
- NCT05821153
- Locations
- πΊπΈ
Alireza Faridar, Houston, Texas, United States
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 20
- Registration Number
- NCT05686226
- Locations
- πΊπΈ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈRWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
- Conditions
- Oropharynx CancerHPV-Associated Cervical CarcinomaHPV-Related CarcinomaHPV-Related MalignancyHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related AdenocarcinomaHPV-Related Adenosquamous CarcinomaHPV-Related Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Endocervical Adenocarcinoma
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 15
- Registration Number
- NCT05639972
- Locations
- πΊπΈ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈRWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
CISH Inactivated TILs in the Treatment of NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05566223
- Locations
- πΊπΈ
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.